Literature DB >> 12451186

Needed in MS: evidence, not EVIDENCE.

Karl Kieburtz1, Michael McDermott.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12451186     DOI： 10.1212/wnl.59.10.1482

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

Review 1.  [Interferon β for multiple sclerosis. How much is good enough?].

Authors:  C Warnke; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

Review 2.  Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors:  Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

3.  What can we learn from failed clinical trials in multiple sclerosis?

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 4.  Multiple sclerosis therapy: an update on recently finished trials.

Authors:  Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd Kieseier; Heinz Wiendl
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 6.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.